Sanuwave Health (SNWV)
NASDAQ:SNWV
Want to see SNWV full AI Analyst Report?
SNWV Stock Chart & Stats
$31.30
$1.30(5.42%)
At close: 4:00 PM EST
$31.30
$1.30(5.42%)
Day’s Range― - ―
52-Week Range$7.53 - $46.59
Previous CloseN/A
Volume17.14K
Average Volume (3M)78.76K
Market Cap
$65.61M
Enterprise Value$89.55M
Total Cash (Recent Filing)$10.78M
Total Debt (Recent Filing)$22.16M
Price to Earnings (P/E)4.3
Beta1.13
Next Earnings
Aug 18, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.76
Shares Outstanding8,598,976
10 Day Avg. Volume75,518
30 Day Avg. Volume78,757
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda3.95
Forecast
1Y Price Target
$47.00Price Target Upside50.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$51.35M
Bulls Say, Bears Say
Bulls Say
Strong Recent Revenue And High Gross MarginsSanuwave’s sharp top-line acceleration and very high gross margin indicate scalable unit economics in wound‑care consumables and therapies. Sustained high margins provide durable operating leverage, supporting reinvestment in commercial expansion and R&D over the next several quarters.
Positive Operating And Free Cash FlowRecent positive operating and free cash flow suggests the business can self-fund growth initiatives and cover working capital needs. Improved cash conversion versus prior years reduces near-term financing pressure and supports sustaining commercial build-out and tax/legal remediation efforts.
Growing Consumables Utilization (recurring Revenue)Rising consumables usage per system points to stronger recurring revenue and higher lifetime value per customer. Durable consumable demand makes revenue less reliant on lumpy capital sales and supports predictable revenue and margin profiles over the coming 2–6 months.
Bears Say
High Leverage And Thin EquityElevated leverage and a thin equity cushion increase financing and covenant risk, limiting strategic flexibility. In an industry exposed to reimbursement shifts, weak balance-sheet resilience can force dilutive financing or constrained investment when reimbursement or sales cycles worsen.
Market Disruption And Cannibalization Of New System SalesCMS-driven reimbursement clawbacks have structurally reduced demand for new capital systems and created a secondary used-equipment market. That dynamic can persist, pressuring long‑term unit growth and making recovery of new-system sales slower and more uncertain over multiple quarters.
Profitability Volatility And Margin PressureMargin pressure from reseller mix, lower ASPs and rising operating expenses increases earnings volatility. Continued investments plus inconsistent gross/profitability trends raise question marks about sustainable net income and limit predictability of free cash flow in the medium term.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $7.53 and its highest was $46.59 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $65.61M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is Aug 18, 2026 which is in 53 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on May 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.03.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Undervalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate is -0.03.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,598,976 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 18.08%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.00 (50.16% Upside)
$47.00 (50.16% Upside)
Blogger Sentiment
Bullish
SNWV Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.00%
12-Months-Change
Fundamentals
Return on Equity
-450.56%
Trailing 12-Months
Asset Growth
20.23%
Trailing 12-Months
Company Description
Sanuwave Health
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. The company was founded on May 6, 2004 and is headquartered in Eden Prairie, MN.
SNWV Company Deck
SNWV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed cautious optimism: underlying demand signs and product adoption are improving (record applicator units, active systems growth, strong consumables usage, a growing large‑account pipeline, maintained full‑year guidance), but near‑term profitability metrics show pressure (gross margin compression, higher operating expenses, negative GAAP EBITDA) driven by reseller mix, one‑time remediation costs and market disruption from CMS actions. Management presents the issues as largely transitory and supported by a strengthening commercial pipeline.View all SNWV earnings summariesSNWV Stock 12 Month Forecast
Average Price Target
$47.00
▲(50.16% Upside)
Technical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
21.99% Insiders
7.35% Mutual Funds
25.22% Other Institutional Investors
37.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---